Home > Resources > Whitepapers > AN OUTLOOK ON US BIOSIMILAR COMPETITION

AN OUTLOOK ON US BIOSIMILAR COMPETITION

The pharmaceutical industry is experiencing change in ways it hasn’t ever before. On the demand side, we are seeing an aging population, increased prevalence of “Western” diseases, and a dramatic growth in global access to pharmaceuticals. On the supply side, we are seeing increased competition from emerging market players, and a shift in the way drugs are being developed, manufactured, and delivered. Meanwhile, policy makers are struggling with an inherent confl ict between desire to provide improved access to better medicines and the need to curb the growth of healthcare expenditures.

Spotlight

Atara Biotherapeutics, Inc.

We launched Atara Biotherapeutics in August 2012 to help patients combat cancer, kidney disease and other illnesses. Our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors as well as allogeneic, or third-party derived, antigen-specific T-cells, to change the course of disease progression.

OTHER WHITEPAPERS

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Understanding Single-Pass Tangential Flow Filtration and the New Era of Bioprocessing

whitePaper | December 22, 2022

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are protected by a portfolio of patents[1-6].

Lipid Nanoparticle and Liposome

whitePaper | September 12, 2022

Lipid nanoparticles (LNPs) and liposomes are variations of lipid-based drug carriers differing in their internal structure.